Samsung Bioepis starts to develop new drug for acute pancreatitis

Published: 2018-08-14 22:54:21

Updated: 2018-08-14 22:54:21

Samsung Bioepis(CEO/President Han-Seung Ko) will start to develop new drugs for acute pancreatitis.

Samsung Bioepis said they would conduct a Phase I clinical trial for an acute pancreatitis therapy candidate(project name: SB26, TAK-671) being developed jointly with Japanese Takeda Pharmaceuticals(CEO Christophe Weber).

Samsung Bioepis acquired the IND approval for the Phase I clinical trial ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.